Get the Stockscreener App
20.74
0.48%
+0.10
Fulgent Genetics Inc stock is currently priced at $20.74, with a 24-hour trading volume of 148.58K.
It has seen a +0.48% increased in the last 24 hours and a -4.91% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $20.73 pivot point. If it approaches the $20.96 resistance level, significant changes may occur.
Previous Close:
$20.64
Open:
$20.51
24h Volume:
148.58K
Market Cap:
$620.14M
Revenue:
$289.21M
Net Income/Loss:
$-167.83M
P/E Ratio:
-12.65
EPS:
-1.64
Net Cash Flow:
$4.80M
1W Performance:
+3.24%
1M Performance:
-4.91%
6M Performance:
-18.06%
1Y Performance:
-30.89%
1D Range:
$20.40
$20.77
52W Range:
$19.88
$44.09
Fulgent Genetics Inc Stock (FLGT) Company Profile
Name
Fulgent Genetics Inc
Sector
Industry
Phone
626-350-0537
Address
4978 Santa Anita Avenue, Temple City
Fulgent Genetics Inc Stock (FLGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-07-23 | Initiated | UBS | Neutral |
| Dec-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-18-22 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Feb-04-22 | Resumed | Piper Sandler | Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Underperform |
| Jan-08-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Nov-24-20 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-20-20 | Initiated | Oppenheimer | Outperform |
| May-29-20 | Initiated | BTIG Research | Buy |
| Nov-05-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Mar-01-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Nov-07-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Fulgent Genetics Inc Stock (FLGT) Latest News
Fulgent Genetics Inc Stock (FLGT) Financials Data
Fulgent Genetics Inc (FLGT) Revenue 2024
FLGT reported a revenue (TTM) of $289.21 million for the quarter ending December 31, 2023, a -53.27% decline year-over-year.
Fulgent Genetics Inc (FLGT) Net Income 2024
FLGT net income (TTM) was -$167.82 million for the quarter ending December 31, 2023, a -217.03% decrease year-over-year.
Fulgent Genetics Inc (FLGT) Cash Flow 2024
FLGT recorded a free cash flow (TTM) of $4.80 million for the quarter ending December 31, 2023, a -97.87% decrease year-over-year.
Fulgent Genetics Inc (FLGT) Earnings per Share 2024
FLGT earnings per share (TTM) was -$5.64 for the quarter ending December 31, 2023, a -223.68% decline year-over-year.
About Fulgent Genetics Inc
Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions. It markets its tests through internal sales force, as well as through independent sales representatives in the United States, Canada, the People's Republic of China, and internationally. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
0.01%
0.98%
Cap:
|
Volume (24h):